How much funding has Avidity Biosciences raised?

Avidity Biosciences has raised $136.8M in total funding, most recently a Series A round.

Who are Avidity Biosciences's investors?

Avidity Biosciences's investors include RTW Investments, Eli Lilly, Takeda (JP), Alexandria Venture Investments, EcoR1 Capital, F-Prime Capital.

When was Avidity Biosciences founded?

Avidity Biosciences was founded in 2012.

Where is Avidity Biosciences headquartered?

Avidity Biosciences is headquartered in San Diego, California, United States.

What industry is Avidity Biosciences in?

Avidity Biosciences operates in Biotech, Healthcare.

How many employees does Avidity Biosciences have?

Avidity Biosciences has 201-500 employees.

Avidity Biosciences

Closed

Revolutionizing the Delivery of RNA Therapeutics

San Diego, United States · Founded 2012 · $136.8M raised

Biotech

Healthcare

Headquarters: San Diego, California
Employees: 201–500
Founded: 2012
Business Model: B2B

Website: aviditynano.com
Total Funding: $136.8M
Last Round: $5.8M Series ANov 2019
Rounds: 5

About

Avidity Biosciences is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on revolutionizing RNA therapeutics through its proprietary Antibody Oligonucleotide Conjugate (AOC) platform. AOCs combine the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies to target genetic drivers of diseases previously untreatable with RNA therapeutics. The company led the field with the first successful targeted RNA delivery into muscle tissue and has three clinical development programs for rare muscle diseases — myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). Avidity was acquired by Novartis in February 2026.

Summary

Avidity Biosciences is a Biotech company based in San Diego, United States, founded in 2012. It has raised $136.8M in total across 5 rounds, most recently a $5.8M Series A round in Nov 2019. Investors include RTW Investments, Eli Lilly and Takeda (JP).